Literature DB >> 17947392

Hyperforin down-regulates effector function of activated T lymphocytes and shows efficacy against Th1-triggered CNS inflammatory-demyelinating disease.

Anna Cabrelle1, Isabella Dell'Aica, Luca Melchiori, Samuela Carraro, Enrico Brunetta, Raffaele Niero, Elisa Scquizzato, Giulia D'Intino, Laura Calzà, Spiridione Garbisa, Carlo Agostini.   

Abstract

Hyperforin (Hyp) is an active compound contained in the extract of Hypericum perforatum, well known for its antidepressant activity. However, Hyp has been found to possess several other biological properties, including inhibitory effects on tumor invasion, angiogenesis, and inflammation. In this paper, we show that treatment with Hyp inhibited IFN-gamma production, with down-regulation of T-box (T-bet; marker of Th1 gene expression) and up-regulation of GATA-3 (marker gene of Th2) on IL-2/PHA-activated T cells. In parallel, we showed a strong down-regulation of the chemokine receptor CXCR3 expression on activated T cells. The latter effect and the down-modulation of matrix metalloproteinase 9 expression may eventually lead to the inhibition of migratory capability and matrix traversal toward the chemoattractant CXCL10 by activated lymphocytes that we observed in vitro. The effect of Hyp was thus evaluated on an animal model of experimental allergic encephalomyelitis (EAE), a classic, Th1-mediated autoimmune disease of the CNS, and we observed that Hyp attenuates the severity of the disease symptoms significantly. Together, these properties qualify Hyp as a putative, therapeutic molecule for the treatment of autoimmune inflammatory disease sustained by Th1 cells, including EAE.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17947392     DOI: 10.1189/jlb.0707469

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  6 in total

Review 1.  Ethnobotany as a pharmacological research tool and recent developments in CNS-active natural products from ethnobotanical sources.

Authors:  Will C McClatchey; Gail B Mahady; Bradley C Bennett; Laura Shiels; Valentina Savo
Journal:  Pharmacol Ther       Date:  2009-05-05       Impact factor: 12.310

2.  Identification of light-independent inhibition of human immunodeficiency virus-1 infection through bioguided fractionation of Hypericum perforatum.

Authors:  Wendy Maury; Jason P Price; Melinda A Brindley; ChoonSeok Oh; Jeffrey D Neighbors; David F Wiemer; Nickolas Wills; Susan Carpenter; Cathy Hauck; Patricia Murphy; Mark P Widrlechner; Kathleen Delate; Ganesh Kumar; George A Kraus; Ludmila Rizshsky; Basil Nikolau
Journal:  Virol J       Date:  2009-07-13       Impact factor: 4.099

3.  Tetrahydrohyperforin and octahydrohyperforin are two new potent inhibitors of angiogenesis.

Authors:  Beatriz Martínez-Poveda; Luisella Verotta; Ezio Bombardelli; Ana R Quesada; Miguel Angel Medina
Journal:  PLoS One       Date:  2010-03-09       Impact factor: 3.240

4.  Hyperforin, an Anti-Inflammatory Constituent from St. John's Wort, Inhibits Microsomal Prostaglandin E(2) Synthase-1 and Suppresses Prostaglandin E(2) Formation in vivo.

Authors:  Andreas Koeberle; Antonietta Rossi; Julia Bauer; Friederike Dehm; Luisella Verotta; Hinnak Northoff; Lidia Sautebin; Oliver Werz
Journal:  Front Pharmacol       Date:  2011-02-18       Impact factor: 5.810

5.  Gender effect on neurodegeneration and myelin markers in an animal model for multiple sclerosis.

Authors:  Alessandro Massella; Giulia D'Intino; Mercedes Fernández; Sandra Sivilia; Luca Lorenzini; Silvia Giatti; Roberto C Melcangi; Laura Calzà; Luciana Giardino
Journal:  BMC Neurosci       Date:  2012-01-24       Impact factor: 3.288

6.  Enhancing the efficacy of Hypericum perforatum in the treatment of an experimental model of multiple sclerosis using gold nanoparticles: an in vivo study.

Authors:  Mahmoud Mahmoudi; Maryam Rastin; Mohammad Kazemi Arababadi; Akbar Anaeigoudari; Reza Nosratabadi
Journal:  Avicenna J Phytomed       Date:  2022 May-Jun
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.